Antineoplastic Syst Enzyme Inhibitors/Apalutamide Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Apalutamide may speed up how quickly your liver processes your other cancer medicine.Apalutamide may also affect your heart's rhythm. Your other cancer medicine may have the same effect.
What might happen:
The amount of your cancer medicine in your blood may decrease and it may not work as well.Taking apalutamide with other medicines that can affect your heart rhythm may increase your risk of irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to monitor a test called an electrocardiogram (ECG) while you are taking apalutamide to see if it is affecting your heart's rhythm. Let your doctor know right away if you notice an irregular heartbeat, dizziness or have any fainting episodes. Your doctor may want to adjust your medicines.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Erleada (apalutamide) US prescribing information. Janssen Biotech, Inc. July, 2021.
- 2.Zykadia (ceritinib) US prescribing information. Novartis Pharmaceuticals Corporation August, 2021.
- 3.Xalkori (crizotinib) US prescribing information. Pfizer Inc. September, 2023.
- 4.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company February, 2023.
- 5.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline December, 2018.
- 6.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation September, 2021.
- 7.Votrient (pazopanib) US prescribing information. GlaxoSmithKline August, 2020.
- 8.Nexavar (sorafenib) US prescribing information. Bayer Pharmaceuticals Corporation July, 2020.
- 9.Sutent (sunitinib malate) US prescribing information. Pfizer Inc. August, 2021.
- 10.Caprelsa (vandetanib) US prescribing information. AstraZeneca Pharmaceuticals LP October, 2018.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.